We are live on ! Find out more
ALNY icon

Alnylam Pharmaceuticals
ALNY

784 hedge funds and large institutions have $40.1B invested in Alnylam Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 87 funds opening new positions, 319 increasing their positions, 280 reducing their positions, and 80 closing their positions.

New
Increased
Maintained
Reduced
Closed

113% more call options, than puts

Call options by funds: $453M | Put options by funds: $213M

67% more funds holding in top 10

Funds holding in top 10: 3 → 5 (+2)

14% more repeat investments, than reductions

Existing positions increased: 319 | Existing positions reduced: 280

9% more first-time investments, than exits

New positions opened: 87 | Existing positions closed: 80

0.64% more ownership

Funds ownership: 99.08% → 99.72% (+0.64%)

1% less funds holding

Funds holding: 791 → 784 (-7)

8% less capital invested

Capital invested by funds: $43.4B → $40.1B (-$3.32B)

Holders
784
Holders Change
-7
Holders Change %
-0.88%
% of All Funds
9.47%
Holding in Top 10
5
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+66.67%
% of All Funds
0.06%
New
87
Increased
319
Reduced
280
Closed
80
Calls
$453M
Puts
$213M
Net Calls
+$240M
Net Calls Change
-$5M

Top Buyers

Rank Fund Capital Flow
1
DTC
Deep Track Capital
Connecticut
+$249M
2
OAG
Orbis Allan Gray
Bermuda
+$197M
3
Los Angeles Capital Management
Los Angeles Capital Management
California
+$193M
4
PBA
Paradigm Biocapital Advisors
New York
+$145M
5
BlackRock
BlackRock
New York
+$140M

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$1.1B
2
Marshall Wace
Marshall Wace
United Kingdom
-$253M
3
Invesco
Invesco
Georgia
-$96.8M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$85.5M
5
Allspring Global Investments
Allspring Global Investments
North Carolina
-$84.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
MEG
726
Millstone Evans Group
Colorado
$3.01K -$9.05K -30 -75%
AIC
727
Archer Investment Corporation
Indiana
$3.01K – – –
HPWM
728
High Point Wealth Management
New Jersey
$3.01K – – –
MSFP
729
Mark Sheptoff Financial Planning
Connecticut
$3.01K – – –
NSIM
730
North Star Investment Management
Illinois
$3.01K +$905 +3 +43%
WA
731
Westfuller Advisors
New York
$2.71K +$603 +2 +29%
DPW
732
DiNuzzo Private Wealth
Pennsylvania
$2.41K – – –
ANBT
733
American National Bank & Trust
Texas
$2.41K +$2.41K +8 New
PS
734
Planning Strategies
Pennsylvania
$2.41K +$2.41K +8 New
Kayne Anderson Rudnick Investment Management
735
Kayne Anderson Rudnick Investment Management
California
$2.23K +$1.51K +5 +250%
ACA
736
American Capital Advisory
Idaho
$2.11K +$603 +2 +40%
PCM
737
Penserra Capital Management
California
$2K – – –
WCM
738
Winthrop Capital Management
Indiana
$2K +$603 +2 +50%
MAM
739
Marquette Asset Management
Minnesota
$1.81K – – –
RWS
740
Retirement Wealth Solutions
Wisconsin
$1.81K – – –
ADL
741
Asset Dedication LLC
California
$1.81K +$302 +1 +20%
HWA
742
Heritage Wealth Advisors
Virginia
$1.81K – – –
FRA
743
Front Row Advisors
California
$1.55K – – –
DF
744
Dunhill Financial
United Kingdom
$1.5K – – –
LWM
745
Lodestone Wealth Management
Washington
$1.5K – – –
NRG
746
Nemes Rush Group
Michigan
$1.5K – – –
MA
747
Montag & Associates
Georgia
$1.41K – – –
BHWM
748
Beaird Harris Wealth Management
Texas
$1.21K – – –
JFA
749
JNBA Financial Advisors
Minnesota
$1.21K – – –
CCMI
750
Creative Capital Management Investments
California
$1.2K +$1.21K +4 New
28 29
30
31 32

ALNY Hedge Fund Activity: Q2 2026 in Review

784 of the 8,279 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q2 2026, worth a combined $40.1B — down 7.7% from $43.4B a quarter earlier.

Buyers outnumbered sellers: 87 funds opened new ALNY positions and 80 closed out — a net gain of 7 holders — while 319 added to existing stakes and 280 trimmed.

The largest buyer was Deep Track Capital, opening a new position worth an estimated $249M. The largest seller was JP Morgan Chase, cutting an estimated $1.1B.

  • 784 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q2 2026, down from 791 in Q1 2026.
  • Funds reported $40.1B of Alnylam Pharmaceuticals stock for Q2 2026, down 7.7% quarter-over-quarter.
  • 87 funds opened new Alnylam Pharmaceuticals positions in Q2 2026 and 80 closed out, a net change of +7 holders.
  • The largest Alnylam Pharmaceuticals buyer in Q2 2026 was Deep Track Capital, an estimated $249M added.
  • The largest Alnylam Pharmaceuticals seller in Q2 2026 was JP Morgan Chase, an estimated $1.1B sold.

Based on aggregated 13F filings for Q2 2026.